Total medical devices private equity deals in Q4 2018 worth $2.18bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 108.4% over the previous quarter and a drop of 36.6% when compared with the last four-quarter average, which stood at $3.44bn.
Comparing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $1.26bn. At the country level, France topped the list in terms of deal value at $1.16bn.
In terms of volumes, North America emerged as the top region for medical devices private equity deals globally, followed by Europe and then Middle East and Africa.
The top country in terms of private equity deals activity in Q4 2018 was the United States with 10 deals, followed by the United Kingdom with four and France with two.
In 2018, as of the end of Q4, medical devices private equity deals worth $11.64bn were announced globally, marking an increase of 40.5% year on year.
Medical devices private equity deals in Q4 2018: Top deals
The top five medical devices private equity deals accounted for 93.01% of the overall value during Q4 2018.
The combined value of the top five medical devices private equity deals stood at $2.03bn, against the overall value of $2.18bn recorded for the quarter.
In second place was Gurnet Point Capital’s private equity deal with Corium International for $504m and in third place was D1 Capital , Lux Capital , Mithril Capital Management , Partner Fund Management , Senator Investment Group , Viking Global Investors and Wellington Management’s $220m private equity deal with Auris Health .
Barry’s Tea Holdings, Hayfin Capital Management , Montreux Equity Partners and Oyster Capital Partners ‘ $97m private equity deal with GC Aesthetics and Martin Bauer Group and Shavit Capital Management’s private equity deal with Syqe Medical for $50m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.